NRXS NeurAxis, Inc.
Price Chart
Executive Summary
NeurAxis reported strong revenue growth for Q4 and full-year 2025, with 27% and 33% year-over-year increases, respectively, driven by higher unit sales and new product launches. Despite expanding gross margins and positive operational milestones—including a Category I CPT code and FDA clearance—the company widened its operating loss due to higher selling and legal expenses. Cash balance stands at $5.0 million, with $2.6 million in post-period equity raises.
Key Financial Metrics
Actionable Insight
Traders should monitor upcoming insurance coverage expansions and utilization trends in 2026, as reimbursement infrastructure is now in place. The recent cash raise improves runway, but continued losses and margin pressure suggest near-term dilution risk if growth slows.
Key Facts
- Q4 2025 revenue: $968K, up 27% YoY from $761K
- FY2025 revenue: $3.6M, up 33% YoY from $2.7M
- Gross margin declined to 84.2% in FY2025 from 86.5% in FY2024
- Operating loss increased to $7.8M in FY2025 from $7.2M in FY2024
- Net loss decreased to $7.8M in FY2025 from $8.2M in FY2024 due to absence of prior-year one-time settlements
- Cash balance: $5.0M as of Dec 31, 2025; $2.6M raised post-period via ATM and warrant exercises
- Achieved Category I CPT code for PENFS, FDA clearance expansion, and VA FSS contract
Financial Impact
Revenue up 33% to $3.6M, but operating loss increased to $7.8M; gross margin compression of 130 bps despite volume growth
Risk Factors
- Continued operating losses and negative cash flow from operations ($6.4M used in FY2025)
- Gross margin pressure from discounting in financial assistance programs and low-margin RED device
- Heavy reliance on future payer coverage wins to sustain growth trajectory
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258872 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 12, 2026
28d ago
|
Press Release
| $8.27 $7.41 | ▼ −10.40% | ▼ −10.48% | $6.67 (−19.35%) |
|
May 5, 2026
5w ago
|
Press Release
| $8.69 $8.27 | ▼ −4.83% | ▼ −6.82% | $6.67 (−23.25%) |
|
Apr 28, 2026
6w ago
|
DEFA14A
| $7.44 $8.81 | ▲ +18.41% | ▲ +15.30% | $6.67 (−10.35%) |
|
Apr 21, 2026
7w ago
|
8-K
| $7.51 $7.59 | ▲ +1.07% | ▲ +1.01% | $6.67 (−11.19%) |
|
Apr 21, 2026
7w ago
|
424B5
| $7.51 $7.59 | ▲ +1.07% | ▲ +1.01% | $6.67 (−11.19%) |
|
Apr 10, 2026
8w ago
|
Press Release
| $6.84 $7.22 | ▲ +5.56% | ▲ +1.05% | $6.67 (−2.49%) |
|
Apr 1, 2026
10w ago
|
Insider Cluster
| $7.18 $7.25 | ▲ +0.97% | ▼ −2.79% | $6.67 (−7.10%) |
|
Mar 19, 2026
11w ago
|
Press Release
| $7.16 $7.00 | ▼ −2.23% | ▼ −0.02% | $6.67 (−6.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access